HMPL-760 + HMPL-760 Placebo + R-GemOx
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Trial Timeline
Mar 10, 2026 → Dec 30, 2028
NCT ID
NCT07409428About HMPL-760 + HMPL-760 Placebo + R-GemOx
HMPL-760 + HMPL-760 Placebo + R-GemOx is a phase 3 stage product being developed by HUTCHMED for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07409428. Target conditions include Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
What happened to similar drugs?
0 of 9 similar drugs in Relapsed/Refractory Diffuse Large B-Cell Lymphoma were approved
Approved (0) Terminated (1) Active (8)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07409428 | Phase 3 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory Diffuse Large B-Cell Lymphoma